Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Short-course Blinatumomab in Patients With Detectable Measurable Residual Disease With Philadelphia Chromosome-negative B-cell Acute Lymphoblastyc Leukemia

NCT06886074 is registered in ClinicalTrials.gov with Hospital Universitario Dr. Jose E. Gonzalez as lead sponsor.

NCT NCT06886074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06886074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Short-course Blinatumomab in Patients With Detectable Measurable Residual Disease With Philadelphia Chromosome-negative B-cell Acute Lymphoblastyc Leukemia
Lead sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Phase
Phase 2
Overall status
Recruiting
Start date
January 2, 2025
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, measurable residual disease (mrd)